Exeliom is a preclinical-stage biopharmarceutical company
whose mission is to harness the therapeutic potential of gut microbiota
We are committed to developing a new generation of medicines: monoclonal microbial therapies.
We will use our breakthrough translational approach, our unique relationships with our partners and our passion to devise new ways to prevent and treat diseases.
We are scientists from the fields of medicine, drug development, molecular biology, and process engineering.
Benjamin Hadida co-founded Nextbiotix in December 2016 and has served as Chief Executive Officer since.
Benjamin is an entrepreneur who developed a wide range of competences in various industries : investment banking (UBS), venture capital (Pacific Channel), pharmaceutical regulatory affairs (Amgen), biotech operations (Theravectys), applied research (Vision Institute in Paris).
Benjamin has a Master in Management from ESSEC Business School and a Master in Molecular and Cellular Biology from Pierre and Marie Curie University (UPMC - Sorbonne University).
Co-founder, Chief Executive Officer
Philippe Langella, PhD, is First Class Research Director at the French National Institute of Agricultural Research (INRA).
He founded, and still leads, the Laboratory of Commensals and Probiotics-Host Interactions (MICALIS Institute, INRA, Jouy en Josas, France). He is also the Head of Food and Digestive Ecosystems Department of teh MICALIS Institute.
Philippe Langella has authored more than 200 peer-reviewed international publications at the interface between microbiology and human health.
He is co-inventor of 17 patents in the domain of the use of commensal and probiotic bacteria in health domain. He has participated to numerous national and European research projects and has strong research collaborations with several agro-food and pharmaceutical companies. He’s a referee for many international journals and consulting expert for several agro-food and pharmaceutical companies.
Dr. Philippe Langella
Co-founder, Preclinical Advisor
Harry Sokol, is Professor in the Gastroenterology department of the Saint Antoine Hospital (APHP, Paris, France) and is the head of the Gut Microbiota and Immunity lab (INSERM U1157/UMR CNRS 7203, Sorbonne Université, Paris and INRA Micalis). Harry Sokol is an internationally recognized expert in Inflammatory Bowel Disease (IBD) and in gut microbiota fields. He published over 150 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Nature Medicine). His work on the role of the gut microbiota in IBD pathogenesis led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria Faecalibacterium prausnitzii in gut homeostasis and in IBD. Beside basic science, he is also involved in translational research and he is the current president of the French group of fecal microbiota transplantation.
Prof. Harry Sokol
Co-founder, Clinical Advisor
Patrick Gervais is Emeritus Professor of Process Engineering at AgroSup Dijon.
He founded and led the Microbial and Food Process Engineering laboratory (UMR 02.102 PAM AgroSup Dijon/University of Burgundy).
In parallel, Patrick Gervais developed a research center specialized in industrial transfer and scale-up.
His academic work actively contributes to deepening our understanding of the bacteria cell responses to different environmental stresses.
Patrick Gervais has published over 170 papers in this field and his research led to industrial improvements for pathogens destruction, and for ferments and probiotics viability preservation during their processing.